Aytu BioScience, Inc. (NASDAQ:AYTU) has a beta value of 0.17 and has seen 1,541,021 shares traded in the last trading session. The company, currently valued at $124.44 Million, closed the last trade at $0.99 per share which meant it lost -$0.03 on the day or -3.05% during that session. The AYTU stock price is -202.02% off its 52-week high price of $2.99 and 65.66% above the 52-week low of $0.34. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.96 Million shares traded. The 3-month trading volume is 26.03 Million shares.

The consensus among analysts is that Aytu BioScience, Inc. (AYTU) is a Buy stock at the moment, with a recommendation rating of 1.5. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 2 have rated it as a Hold, with 2 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05.

Aytu BioScience, Inc. (NASDAQ:AYTU) trade information

Despite being -3.05% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, Oct 27 when the AYTU stock price touched $1.02 or saw a rise of 3.05%. Year-to-date, Aytu BioScience, Inc. shares have moved 1.69%, while the 5-day performance has seen it change -2.09%. Over the past 30 days, the shares of Aytu BioScience, Inc. (NASDAQ:AYTU) have changed -16.19%. Short interest in the company has seen 11.18 Million shares shorted with days to cover at 3.09.

Wall Street analysts have a consensus price target for the stock at $2.63, which means that the shares’ value could jump 165.66% from current levels. The projected low price target is $2.25 while the price target rests at a high of $3. In that case, then, we find that the current price level is +203.03% off the targeted high while a plunge would see the stock lose 127.27% from current levels.

Aytu BioScience, Inc. (AYTU) estimates and forecasts

Figures show that Aytu BioScience, Inc. shares have outperformed across the wider relevant industry. The company’s shares have lost -38.96% over the past 6 months, compared to 13.3% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 84.4% and -400% for the next quarter. Revenue growth from the last financial year stood is estimated to be +113.6%.

2 analysts offering their estimates for the company have set an average revenue estimate of $13.33 Million for the current quarter. 2 have an estimated revenue figure of $14.12 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $2.01 Million for this quarter, and analysts expect sales will grow by 563.2% for the current quarter.

Earnings growth for 2020 is a modest +91.3%.

Aytu BioScience, Inc. (NASDAQ:AYTU)’s Major holders

Insiders own 6.24% of the company shares, while shares held by institutions stand at 12.01% with a share float percentage of 12.81%. Investors are also buoyed by the number of investors in a company, with Aytu BioScience, Inc. having a total of 29 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 4.22 Million shares worth more than $6Million. As of June 29, 2020, Vanguard Group, Inc. (The) held 3.36% of shares outstanding.

The other major institutional holder is Blackrock Inc., with the holding of over 1.11 Million shares as of June 29, 2020. The firm’s total holdings are worth over $1.57 Million and represent 0.88% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of June 29, 2020, the former fund manager holds about 2.82% shares in the company for having 3548665 shares of worth $5.04 Million while later fund manager owns 482.77 Thousand shares of worth $574.49 Thousand as of September 29, 2020, which makes it owner of about 0.38% of company’s outstanding stock.

Get The Best Stocks To Trade Every Day!

Join now to get the Marketingsentinel.com pre-market morning brief 100% free